Refla 6

Indications of Refla 6mg Tablet

Refla 6mg Tablet is prescribed in-

• Asthma, anaphylaxis, and severe hypersensitivity responses
• Rheumatoid arthritis, juvenile chronic arthritis, and polymyalgia rheumatica are all examples of rheumatoid arthritis.
• Systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (other than systemic sclerosis), polyartritis nodosa, and sarcoidosis are all examples of autoimmune diseases.
• Pemphigus, bullous pemphigoid, and pyoderma gangrenosum are all types of pemphigus.
• Acute interstitial nephropathy, little change nephrotic syndrome
• Cardiac rheumatoid arthritis
• Crohn's disease, ulcerative colitis
• Optic neuritis, uveitis
• Idiopathic thrombocytopenic purpura, autoimmune hemolytic anaemia
• Acute and lymphatic leukemia, malignant lymphoma, and multiple myeloma are all examples of cancers.
• Immunosuppression in transplant recipients

 

Pharmacology of Refla 6mg Tablet

Phospholipase A2, the enzyme responsible for prostaglandin synthesis, is inhibited by Deflazacort, which has anti-inflammatory properties. Aside from that, Deflazacort inhibits the release of certain chemicals that are crucial to the immune system. Deflazacort suppresses the immune system by reducing the release of these chemicals.

 

Refla 6mg Tablet Administration & Dosage

Adults-

• For acute disorders: Up to 120 mg/day Deflazacort may need to be given initially. Maintenance doses in most conditions are within the range of 3-18 mg/day.
• Rheumatoid arthritis: The maintenance dose is usually within the range of 3-18 mg/day. The smallest effective dose should be used and increased if necessary.
• Bronchial asthma: In the treatment of an acute attack, high doses of 48-72 mg/day may be needed depending on severity and gradually reduced once the attack has been controlled. For maintenance in chronic asthma, doses should be titrated to the lowest dose that controls symptoms.
• Other conditions: The dose of Deflazacort depends on clinical need titrated to the lowest effective dose for maintenance. Starting doses may be estimated on the basis of ratio of 5 mg prednisone or prednisolone to 6 mg.

Children: There has been limited exposure of children to Deflazacort in clinical trials. In children, the indications for glucocorticoids arethe same as for adults, but it is important that the lowest effective dosage is used. Alternate day administration may be appropriate. Doses of Deflazacort usually lie in the range 0.25-1.5 mg/kg/day.

The following ranges provide general guidance:

• Juvenile chronic arthritis: The usual maintenance dose is between 0.25-1.0 mg/kg/day.
• Nephrotic syndrome: Initial dose of usually 1.5 mg/kg/day followed by down titration according to clinical need.
• Bronchial asthma: On the basis of the potency ratio, the initial dose should be between 0.25-1.0 mg/kg on alternate days.

Deflazacort withdrawal: In patients who have received more than physiological doses of systemic corticosteroids (approximately 9 mg per day or equivalent) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced.

 

Interaction

The liver is where Deflazacort is broken down. If you're taking Deflazacort with other drugs that cause liver enzyme induction, such as rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone, or aminoglutethimide, you should up your maintenance dose. It may be possible to reduce the maintenance dose of Deflazacort when taking drugs that inhibit liver enzymes (e.g. ketoconazole).

 

Contraindications

Intolerance to one or more of the ingredients. Patients who are being immunized with a live virus.

 

Refla 6mg Tablet Side Effect

GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; infection susceptibility, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture after recent Ml, thromboembolism

 

Pregnancy & Lactation

Pregnancy: Deflazacort does cross the placenta. In any case, when managed for delayed periods or more than once amid pregnancy, corticosteroids may increment the chance of intrauterine development impediment. As with all drugs, corticosteroids ought to as it were be endorsed when the benefits to the mother and child exceed the risks. Nursing Mother: Corticosteroids are excreted in breast drain, in spite of the fact that no information are accessible for Deflazacort. Measurements of up to 50 mg every day of Deflazacort are improbable to cause systemic impacts within the newborn child. Newborn children of moms taking higher measurements than this may have a degree of adrenal concealment but the benefits of breastfeeding are likely to exceed any hypothetical chance.

 

Precautions & Warnings

The taking after clinical conditions require extraordinary caution and visit quiet checking is necessary- Cardiac malady or congestive heart disappointment (but within the nearness of dynamic rheumatic carditis), hypertension, thromboembolic disarranges. Glucocorticoids can cause salt and water maintenance and expanded excretion of potassium. Dietary salt limitation and potassium supplementation may be necessary. Gastritis or oesophagitis, diverticulitis, ulcerative colitis in case there's the likelihood of approaching puncturing, boil or pyogenic contaminations, new intestinal anastomosis, dynamic or idle peptic ulcer. Diabetes mellitus or family history, osteoporosis, myasthenia gravis, renal insufficiency. Emotional precariousness or insane inclination, epilepsy. Previous corticosteroid-induced myopathy. Liver failure. Hypothyroidism and cirrhosis, which may increment the glucocorticoid effect. Ocular herpes simplex since of conceivable corneal aperture.

 

Therapeutic Class

Glucocorticoids

 

Storage Conditions

Protect from light and moisture by storing below 30°C. Keep the medicine out of children's reach.

 

Pharmaceutical Name